Relapse-free survival At 4 years [clinicaltrials_resource:7af76aa608b2f25d36c7dadc9dc3863a]
Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Relapse-free survival At 4 years [clinicaltrials_resource:7af76aa608b2f25d36c7dadc9dc3863a]
Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.
Bio2RDF identifier
7af76aa608b2f25d36c7dadc9dc3863a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7af76aa608b2f25d36c7dadc9dc3863a
measure [clinicaltrials_vocabulary:measure]
Relapse-free survival
time frame [clinicaltrials_vocabulary:time-frame]
At 4 years
description
Patients receive HER-2/neu int ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:7af76aa608b2f25d36c7dadc9dc3863a
title
Relapse-free survival At 4 years
@en
type
label
Relapse-free survival At 4 yea ...... 76aa608b2f25d36c7dadc9dc3863a]
@en